A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Authors list
Clifford Hudis Charles Swanton Yelena Y Janjigian Ray Lee Stephanie Sutherland Robert Lehman Sarat Chandarlapaty Nicola Hamilton Devika Gajria James Knowles Jigna Shah Keith Shannon Ernestina Tetteh Daniel M Sullivan Carolina Moreno Li Yan Hyo Sook HanAbstract
Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to determine the safety and tolerability of the investigational AKT inhibitor MK-2206, to prepare for future studies to determine whether the combination with trastuzumab could inhibit compensatory signaling.
Full text links
Publisher website (DOI) 10.1186/bcr3577
Europe PubMed Central 24252402
Pubmed 24252402
Keywords
Type of publication
